Curtis Reinard is a Director of Clinical Operations at Context Therapeutics. He is an accomplished Project Leader with over thirteen years of experience in clinical research at the sponsor, contract research organization (CRO), and site level.  He has global expertise in all phases of clinical trials with therapeutic area experience in oncology, immunology and rheumatology.  Prior to joining Context, Curtis was a Senior Global Trial Manager at Bristol-Meyers Squibb where he oversaw all clinical trial activities for his portfolio of studies.

Curtis holds a Bachelor of Science in Business Administration and Marketing from King’s College. He also holds a Master’s in Health Care Administration from King’s College and a Master’s in Regulatory Affairs and Quality Assurance from Temple University.

Megan Schaeffer’s biopharma career spans almost 20 years in multiple cross-functional roles across the drug development process, maintaining a primary focus in oncology. Prior to joining Context, Megan was Vice President, Clinical Operations at Geron Corporation where she was responsible for oversight of all clinical trial activities, clinical operations strategy, planning, and execution, including registrational studies for Geron’s first commercial product, Rytelo^TM (imelstat). Megan spent over a decade at GSK in roles of increasing responsibility across clinical operations, ethics and compliance, and quality. Earlier in her career, Megan worked in clinical operations and quality at PPD and ICON. Megan holds a bachelor’s degree from Chestnut Hill College.

Dr. Schilder is consulting Medical Director at Context Therapeutics. He was previously Director of the Gynecologic Medical Oncology Program at the Kimmel Cancer Center at Jefferson. Prior to his arrival at Thomas Jefferson University Hospital, Dr. Schilder served as a professor in the Department of Medical Oncology and Chief of Gynecologic Medical Oncology at Fox Chase Cancer Center. Dr. Schilder’s research interests include evaluating new treatments for gynecologic malignancies and conducting phase I trials for new drug development. He has written more than 150 book chapters, articles, and abstracts. Dr. Schilder is the former NRG Developmental Therapeutics Gynecologic Cancer Phase I Subcommittee Chair and serves on the advisory boards of several pharmaceutical companies.

A graduate of Rutgers University, Dr. Schilder received both his M.S. and medical degree from the University of Miami. Dr. Schilder’s postgraduate training began at Temple University Hospital with an internship and residency in Internal Medicine. He completed a joint hematology and oncology fellowship at Temple University Hospital and Fox Chase Cancer Center.

Jorie West is Senior Director of Program Management at Context Therapeutics and a program and portfolio management leader in drug development with over 20 years of experience leading complex, cross-functional programs from pre-clinical through post-marketing. She has served as Senior Director of Program Management at small and large biotech and pharmaceutical companies, aligning cross-functional asset teams, driving execution against integrated development plans, and enabling on-time, risk-mitigated milestone delivery through best practices in project planning, critical path and scenario analysis, and data-driven decision-making. Her experience includes overseeing high-value portfolios, implementing enterprise project and portfolio management systems such as Planisware for integrated resource, cost, and timeline oversight, and optimizing clinical development and lifecycle management for multiple complex programs while managing strategic partnerships and alliances. Her core strengths span cross-functional leadership, stakeholder and relationship management, financial and operational planning, governance support, regulatory submission readiness, alliance management, and continuous process improvement, supported by certifications including PMP and CA-AM and specialized training in pharmaceutical strategy and critical chain project management.

Isabella Veneziale currently serves as a Senior Accountant at Context Therapeutics. She brings over three years of finance and accounting experience, focusing on general ledger accounting, financial reporting, and month-end close processes. Prior to joining the company, Ms. Veneziale was a GL Accountant at Gopuff, a privately owned delivery service startup based in Philadelphia.

Ms. Veneziale holds a B.S. in Finance from The Pennsylvania State University..

Erin Zebrowski is the Senior Director of Quality at Context Therapeutics. She is responsible for all aspects of GMP/GCP/GLP quality for the organization. Erin has more than 15 years’ experience in the pharmaceutical industry in various analytical and quality assurance roles. Prior to joining Context, she has held various technical positions at Becton Dickinson, UPM Pharmaceuticals, Nutramax Laboratories, Eisai Inc., Epicur Pharma, and TG Therapeutics.

Erin holds a BS degree in Chemistry from York College of Pennsylvania and an MPS in Biotechnology (Regulatory Track) from University of Maryland Baltimore County.